Eli Lilly's approved blood cancer therapy Jaypirca helped delay progression of the disease in previously untreated patients ...

Eli Lilly (LLY) recently announced positive results from its Phase 3 BRUIN CLL-313 trial, revealing significant ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Eli Lilly is inviting early-stage biotechs to make use of drug discovery models that the pharma is providing via a new AI ...

Insitro, Firefly Bio and Superluminal Medicines are among the first participants in Lilly’s “TuneLabs” platform, which the pharma says can help young drugmakers while training its own models.

Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why ...

Baron Funds, an investment management company, released its “Baron Fifth Avenue Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 13.4% ...

New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes lose a significant amount of weight.

The restructuring marks the first major action authorised by new CEO Mike Doustdar in a bid to turn the company’s fortunes ...